Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
-
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
-
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
-
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
-
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
-
Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial
-
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
-
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
-
Gyre Announces Publication of Protocol for Phase 3 Trial of F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology